MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Files An 8-K Other Events

MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Files An 8-K Other Events
Item 8.01

We met with investors and potential partners to discuss ARTIVedaTM. The information is filed herewith.

Press release

On Jan 13, 2020 we issued press release stating the interim analysis of ARTI-19. The press release if filed herewith.

ARTIVeda is Mateon’s lead Ayurvedic drug against COVID-19 in India and is being developed by Mateon in partnership with Windlas Biotech Private Limited (India). ARTI-19 India is being conducted by Windlas as part of Mateon’s global effort to deploy ARTIVeda across India, Africa, and Latin America. These interim results are based on 60 randomized patients (out of 114 randomized to date) across 3 sites in India:

(d) Exhibits.

99.1 ARTIVedaTM Product Information Filed herewith.
99.2 Press release – Interim Analysis of ARTI-19 Filed herewith

––


MATEON THERAPEUTICS INC Exhibit

To view the full exhibit click here

Story continues below

About MATEON THERAPEUTICS, INC. (OTCMKTS:MATN)

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

An ad to help with our costs